Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders (2009 - 2026)
Neurocrine Biosciences' Net Income towards Common Stockholders came in at $206.5 million for Q3 2026, down 1.4% from $209.5 million a year earlier but up 43.0% from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends
Over the trailing twelve months to Sep 30, 2026, Neurocrine Biosciences reported Net Income towards Common Stockholders of $702.5 million, up 64.1% year-over-year; for FY2025, it was $478.6 million, up 40.2% from FY2024.
- Net Income towards Common Stockholders has increased in each of the last four years, with a five-year compound annual growth rate of 3.3% (FY2020 to FY2025).
- Going back by year, Net Income towards Common Stockholders was $341.3 million in FY2024 (+36.7%), $249.7 million in FY2023 (+61.6%), $154.5 million in FY2022 (+72.4%) and $89.6 million in FY2021 (-78.0%).
- The five-year range for quarterly Net Income towards Common Stockholders is -$76.6 million (Q1 2023) to $209.5 million (Q3 2025).
- Year-over-year, Net Income towards Common Stockholders increased in four of the last seven quarters, with growth averaging 13.8%.
- The fastest year-over-year change in Net Income towards Common Stockholders over five years came in Q3 2022 (growth of 204.4%), and the weakest in Q1 2025 (a decline of 81.8%).
- Business Quant data shows NBIX's Net Income towards Common Stockholders at $144.4 million (Q2 2026), $197.9 million (Q1 2026) and $153.7 million (Q4 2025) in the three quarters before Q3 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 6.45 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 4.22 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 5.07 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 3.12 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 3.86 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 2.43 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 3.24 Bn |
| 10 | Neurocrine Biosciences | 17.13 Bn | 13.21 Bn | 1.10 Bn | 206.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 206.50 Mn |
| Jun 30, 2026 | 144.40 Mn |
| Mar 31, 2026 | 197.90 Mn |
| Dec 31, 2025 | 153.70 Mn |
| Sep 30, 2025 | 209.50 Mn |
| Jun 30, 2025 | 107.50 Mn |
| Mar 31, 2025 | 7.90 Mn |
| Dec 31, 2024 | 103.10 Mn |
| Sep 30, 2024 | 129.80 Mn |
| Jun 30, 2024 | 65.00 Mn |
| Mar 31, 2024 | 43.40 Mn |
| Dec 31, 2023 | 147.70 Mn |
| Sep 30, 2023 | 83.10 Mn |
| Jun 30, 2023 | 95.50 Mn |
| Mar 31, 2023 | -76.60 Mn |
| Dec 31, 2022 | 89.00 Mn |
| Sep 30, 2022 | 68.50 Mn |
| Jun 30, 2022 | -16.90 Mn |
| Mar 31, 2022 | 13.90 Mn |
| Dec 31, 2021 | -7.30 Mn |
API Access
Neurocrine Biosciences Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();